WOCKPHARMA2,219.90

Wockhardt Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersBIOCONSYNGENEASTERDMGLANDPPLPHARMACOHANCELALPATHLABNATCOPHARMMcap ₹35,962 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations2,798.03,012.03,373.03,564.0
Other Income83.062.0111.0122.0
Total Income2,881.03,074.03,484.03,686.0
Expenses
+ Cost of Materials Consumed620.0612.0674.0739.0
+ Purchases of Stock-in-Trade559.0573.0586.0555.0
+ Changes in Inventories-14.0-53.0-128.0-106.0
+ Employee Benefit Expense629.0651.0725.0757.0
+ Finance Costs305.0254.0213.0217.0
+ Depreciation & Amortisation223.0217.0227.0226.0
+ Other Expenses965.0836.0864.0847.0
Total Expenses3,287.03,090.03,161.03,235.0
EBITDA39.0393.0652.0772.0
EBIT-184.0176.0425.0546.0
Profit
PBT before Exceptional Items-406.0-16.0323.0451.0
+ Exceptional Items-14.00.0-85.012.0
Pretax Income-420.0-16.0238.0463.0
+ Current Tax16.07.018.021.0
+ Deferred Tax36.034.021.028.0
Tax Expense52.041.039.049.0
Net Income-472.0-57.0199.0414.0
+ Net Income — Continuing Ops-472.0-57.0199.0414.0
+ Other Comprehensive Income6.071.0419.0285.0
Total Comprehensive Income-466.014.0618.0699.0
Net Income to Common-463.0-47.0213.0409.0
Minority Interest-9.0-10.0-14.05.0
Per Share
Basic EPS-32.05-3.0213.1225.20
Diluted EPS-32.05-3.0213.1025.19
Other Comprehensive Income — detail
+ Other Comprehensive Income71.0419.0285.0
+ Items NOT to be Reclassified to P&L-8.0-5.070.070.0
+ Items to be Reclassified to P&L14.076.0349.0215.0
Comprehensive Income — Owners of Parent-461.013.0581.0648.0
Comprehensive Income — Non-controlling Interests-5.01.037.051.0
Per Share — as-filed variants
Basic EPS — Continuing Operations-32.05-3.0213.1225.20
Diluted EPS — Continuing Operations-32.05-3.0213.1025.19
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,633.01,880.02,241.02,376.0
Gross Margin %58.3662.4266.4466.67
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-406.0-16.0323.0451.0
− Exceptional Items (reconciliation)-14.00.0-85.012.0
Net Income Adj (tax-effected)-458.0-57.0270.1403.3
EPS Adj-31.10-3.0217.8124.55
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.005.005.00
Paid Up Equity Capital77.081.081.081.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.